Targeting the roots of cancer

Stemergie develops treatments and diagnostics for cancers by targeting cancer-initiating cells (CIC), the roots of cancer.

Stemergie's CIC based technology platform allows the identification, validation and development of treatments against brain CIC. With its proprietary methodology Stemergie is able to identify, isolate and enrich CIC independently of markers. Stemergie plans to translate this technology to further types of CIC, in order to treat and diagnose melanoma as well as further oncology indications.

Stemergie has identified and validated molecules that specifically eradicate brain CIC. This CIC-targeting approach in combination with the current standard of care has a high potential to increase the survival rate of the brain tumor patient in the future. Stemergie is a spin-off company from the Geneva University Hospital (HUG) and the University of Geneva (UNIGE).

For interested investors, please contact us directly under daniel.leutenegger[at]stemergie.com